We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,612

Stakeholders Voice Opinions About Modernizing “Healthy” at FDA Meeting
  • Shook Hardy & Bacon LLP
  • USA
  • March 17 2017

Concerns about how or whether the term "healthy" should be used in food labeling and packaging prompted the U.S. Food and Drug Administration (FDA


Study Claims Honeybee Gut Bacteria “Perturbed” by Antibiotics
  • Shook Hardy & Bacon LLP
  • USA
  • March 17 2017

A study has purportedly suggested that antibiotic treatments for foulbrood and other pathogens can disrupt the gut microbiota of honeybees


FDA refuses to re-classify tooth-whitening products as drugs
  • Shook Hardy & Bacon LLP
  • USA
  • May 2 2014

The U.S. Food and Drug Administration (FDA) has denied a Citizen Petition asking the agency to re-categorize tooth-whitening products as drugs


FDA issues warning to star scientific for antabloc and CigRx products
  • Shook Hardy & Bacon LLP
  • USA
  • January 9 2014

The U.S. Food and Drug Administration (FDA) has warned former Star Scientific, Inc. CEO Jonnie Williams that the company makes therapeutic claims for


FDA steps up issuance of warning letters to cosmetic and dietary supplement companies
  • Shook Hardy & Bacon LLP
  • USA
  • April 1 2015

The Food and Drug Administration (FDA) has issued a number of Warning Letters to cosmetic and dietary supplement companies over the last several


DMAA cleared as cause of soldiers’ deaths
  • Shook Hardy & Bacon LLP
  • USA
  • August 15 2013

A safety review panel formed by the U.S. Army and Department of Defense (DOD) has issued a report which concludes that although DMAA (1


Landmark Texas Supreme Court decision: learned intermediary doctrine applies in prescription drug cases, no DTC exception
  • Shook Hardy & Bacon LLP
  • USA
  • June 12 2012

Addressing the issue squarely for the first time, the Texas Supreme Court has unanimously adopted the learned intermediary doctrine in the prescription drug context thereby confirming that manufacturers are only obligated to warn doctors of the risks of prescription medicines


FDA issues final rule on mica-based pearlescent pigments in distilled spirits
  • Shook Hardy & Bacon LLP
  • USA
  • October 2 2015

The U.S. Food and Drug Administration (FDA) has issued a final rule allowing "the safe use of mica-based pearlescent pigments prepared from titanium


Prop. 65 litigation ends in agreements to remove cocamide DEA from products
  • Shook Hardy & Bacon LLP
  • USA
  • May 22 2014

According to the Center for Environmental Health (CEH), which has sued some 150 personal-care product companies for failing to warn consumers about


Does consumer awareness of food addiction affect eating behavior?
  • Shook Hardy & Bacon LLP
  • USA
  • April 24 2015

Raising concerns about how the media portrays the concept of food addiction, a new study questions whether endorsement of this model "may cause